A Randomized Prospective Evaluation of Leuprolide versus Diethylstilbestrol in the Treatment of Stage D2 Metastatic Prostate Cancer: Results of a Multicenter Study

  • Marc B. Garnick
  • Linda J. Swanson
  • Devorah T. Max


For the past 40 years since the observation by Huggins and Hodges that surgical castration or diethylstilbestrol (DES) could bring relief of symptoms from metastatic prostate cancer, these have been the standard therapies for the initial treatment of that disease (1,2). However, during that time the search for less toxic and more acceptable forms of therapy has continued.


Acid Phosphatase Bone Pain Metastatic Prostate Cancer LHRH Agonist Hormonal Manipulation 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Huggins, C. and Hodges, C.V. Studies on prostatic cancer. I.The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. Cancer Res. 1:293–297, 1941.Google Scholar
  2. 2.
    Huggins, C., Stevens, R.E., Jr. and Hodges, C.V. Studies on prostatic cancer. II. The effects of castration on advanced carcinoma of the prostate gland. Arch. Surg.,43:209–223, 1941.Google Scholar
  3. 3.
    Belchetz, P.E., Plant, T.M., Nakai, Y., Keogh, E.J. andKnobil, E.. Hypophysial responses to continuous and intermittent delivery of hypothalamic gonadotrophin-releasing hormone. Science 202:631–633, 1978.PubMedCrossRefGoogle Scholar
  4. 4.
    Linde, R., Doelle, G.C., Alexander, N., Kirchner, F., Vale, W., Rivier, and J., Rabin, D. Reversible inhibition of testicular steroidogenesis and spermatogenesis by a potent gonadotrophin-releasing hormone agonist in normal men: an approach toward the development of a male contraceptive. New Eng. J. Med. 305:663–667, 1981.PubMedCrossRefGoogle Scholar
  5. 5.
    Ahmed, S.R., Brooman, P.J.C., Shalet, S.M., Howell, A., Blacklock, N.J. and Rickards, D. Treatment of advanced prostatic cancer with LHRH analogue ICI 118630: clinical response and hormonal mechanisms. Lancet 2:415–419, 1983.PubMedCrossRefGoogle Scholar
  6. 6.
    Allen, J.M., O’Shea, J.P., Mashiter, K, Williams, G. and Bloom, S.R. Advanced carcinoma of the prostate: treatment with a gonadotrophin releasing agonist. Br. Med. Journal 286:1607–1609, 1983.CrossRefGoogle Scholar
  7. 7.
    Borgmann, Hardt W., Schmidt-Gollwitzer, M., Adenauer, H. and Nagel, R. Sustained suppression of testosterone production by the luteinizing-hormone releasing-hormone agonist buserelin in patients with advanced prostate carcinoma: a new therapeutic approach? Lancet 1:1097–1099, 1982.PubMedCrossRefGoogle Scholar
  8. 8.
    Faure, N., Lemay, A., Laroche, B., et al. Preliminary results on the clinical efficacy and safety of androgen inhibition by the LHRH agonist alone or combined with an antiandrogen in the treatment of prostatic carcinoma. The Prostate 4:601- 624, 1983.PubMedCrossRefGoogle Scholar
  9. 9.
    Garnick, M.B. and Glode, L.M. for the leuprolide Study Group. Leuprolide versus diethylstilbestrol for metastatic prostate cancer. New Engl. J. Med. 311:1281–1286, 1984.CrossRefGoogle Scholar
  10. 10.
    Koutsilieris, M. and Tolis, G. Gonadotrophin-releasing hormone agonist analogues in the treatment of advanced prostatic carcinoma. The Prostate 4:569–577, 1983.PubMedCrossRefGoogle Scholar
  11. 11.
    Walker, K.J., Nicholson, R.I., Turkes, A.O., et al. Therapeutic potential of the LHRH agonist, IC 118630, in the treatment of advanced prostatic cancer. Lancet 2:413–415, 1983.PubMedCrossRefGoogle Scholar
  12. 12.
    Waxman, J.H., Wass, J.A.H., Henry, W.F., et al. Treatment with gonadotrophin releasing hormone analogue in advanced prostatic cancer. Br. Med. J. 286:1309–1312, 1983.CrossRefGoogle Scholar
  13. 13.
    Schmidt, J.D., Scott, W.W., Gibbons R., et al. Chemotheapy programs of the National Prostatic Cancer Project. Cancer 45:1937–1946, 1980.PubMedGoogle Scholar
  14. 14.
    Warner, B., Worgul T.J., Drago, J., et al. Effect of very highdose D-luecine -gonadotrophin-releasing hormone proethylamide on the hypothalamic-pituitary testicular axis in patients with prostatic cancer. Clin. Invest. 7:1842–1853, 1983.Google Scholar
  15. 15.
    Robinson, M.R. and Thomas, B. Effect of hormonal therapy on plasma testosterone levels in prostatic carcinoma. Br. J. Med. 4:391–394, 1971.CrossRefGoogle Scholar

Copyright information

© Plenum Press, New York 1988

Authors and Affiliations

  • Marc B. Garnick
    • 1
  • Linda J. Swanson
    • 2
  • Devorah T. Max
    • 2
  1. 1.Dana-Farber Cancer InstituteBostonUSA
  2. 2.Abbott LaboratoriesNorth ChicagoUSA

Personalised recommendations